Researchers at Beth Israel Deaconess Medical Center and Harvard Medical School have worked together to create an analysis of breast cancer pathology that incorporates artificial intelligence. They found that their system--and the evaluation by pathologists themselves--worked better when used in conjunction than either did alone.
A Department of Energy lab has devised a new component for 3-D molecular breast imagers that could increase sixfold the contrast of tumors while preserving image quality, with the potential to halve the radiation dose to patients undergoing imaging.
Australian device company AirXpanders has raised AU$20 million (US$15 million) in a private placement in anticipation of an FDA clearance--and subsequent U.S. launch in the first quarter of 2017--for its novel tissue expansion tech for women undergoing breast reconstruction after mastectomy.
Myriad Genetics has acquired Siemens spinout Sividon Diagnostics for €35 million ($39.1 million) up front with the potential for €15 million ($16.8 million) in performance-based milestones.
The use of 3-D mammography to complement a standard 2-D approach in breast cancer screening is becoming more standard. But all previous FDA approvals of mammography systems have included a combination of both 3-D and 2-D approaches. Now, Siemens has nabbed the first FDA approval for a 3-D digital breast tomosynthesis system.
New data indicates that 3-D mammography (or tomosynthesis), when added to standard digital mammography, can result in fewer patients being recalled for follow-up and more accurate cancer diagnosis.
The American Cancer Society has partnered with Samsung and software startup Breezie to conduct a pilot program to offer breast cancer patients a single point of contact across their medical team, family and caregivers as well as to offer access to customized treatment and clinical trial information and an online support group.
Saudi Arabian researchers are deploying single-walled carbon nanotubes as drug delivery agents in the fight against breast cancer.
The interaction between breast cancer cells and a receptor protein called EPHA2 helps explain how the cancer spreads through the body, according to a prominent group of investigators looking for new ways to fight cancer.
Pfizer's Ibrance has been steamrolling since it nabbed an early FDA go-ahead last February. And even with competition coming up the pipeline from the company's Big Pharma rivals, Pfizer intends to keep it that way.